Plant-derived EVs (PDEVs) and mammalian EVs share the same fundamental structure. Both are nanoscale particles bounded by a lipid bilayer membrane that encloses a cargo of proteins, nucleic acids, and signalling lipids. From the level of basic particle architecture, the two modalities are siblings. From the level of biology, manufacturing, and clinical evidence, they belong in different conversations. Treating "EV" as a single commercial category obscures the differences that actually matter.
Biological origin and cargo
Mammalian EVs are produced inside evolutionarily conserved signalling systems. Their surface proteins, including the tetraspanin family (CD9, CD63, CD81), engage cognate receptors on human target cells with high biological precision. Cargo molecules carried by mammalian EVs, including growth factors, cytokines, and regulatory RNAs, were shaped by the same selection pressures that produced the human cell receptors they act on.
Plant-derived EVs carry plant-specific cargo. The signalling proteins, regulatory miRNAs, and lipid species are products of plant biology, not mammalian. What the cross-kingdom literature has established over the past decade is that several functional categories of that cargo, including antioxidant enzymes, heat shock proteins, signalling lipids, and certain RNA species, retain biological activity in mammalian cells under preclinical conditions. The mechanism is not that plant proteins map perfectly to human receptors. The mechanism is that plants evolved bioactive molecules of broad chemical and structural utility, many of which have downstream effects in human cells that are now well characterized.
Safety profile
Mammalian EVs from allogeneic sources require rigorous donor screening for transmissible pathogens, viral contamination, and cellular impurities. Donor variability is a real and unresolved manufacturing constraint. Even autologous mammalian EV preparations require quality testing on every collection.
Plant-derived EVs carry no risk of transmitting human pathogens. Botanical biomass does not host the viruses, prions, or human cellular components that drive most safety screening for mammalian EV manufacturing. There is no donor variability because there is no donor. For cosmetic topical use, this gives plant-derived EVs a clear and uncontroversial safety profile advantage.
Manufacturing and scalability
Mammalian EV production requires GMP-grade cell culture, validated cell banking, and tightly controlled bioreactor systems. The cell line itself is part of the regulated raw material. The economics scale poorly. A clinical-grade mammalian EV manufacturing run can consume hundreds of litres of cell culture media to produce a kilogram-scale order of EV-active material.
Plant-derived EVs are isolated from botanical biomass. The biomass is renewable, agriculturally scalable, and orders of magnitude cheaper than mammalian cell culture per unit of EV yield. The unit economics work at commercial scale in a way that mammalian EV production does not, at least not yet. This is the primary reason plant-derived EVs are the rational entry point for a commercially viable EV dermocosmetic.
Scientific evidence base
Mammalian EVs, especially mesenchymal stem cell-derived (MSC-EV) preparations, have a substantially deeper clinical literature. Wound healing, inflammatory disease, and certain neurology applications are the areas with the most published evidence. Multiple early-phase trials are active.
Plant-derived EV research has a younger but rapidly growing literature. The cross-kingdom signalling work, the cargo characterization work, and the topical bioavailability work are well represented in peer-reviewed journals. The clinical literature for cosmetic applications is earlier in development. Honest framing of the field requires holding both: there is enough preclinical evidence to support topical cosmetic positioning of well-characterized plant-derived EVs, and there is not yet enough clinical evidence to make therapeutic-grade claims that mammalian MSC-EVs can defensibly make.
MISEV2023 characterization standards apply to both. NTA-verified particle counts, size distribution, EV-associated protein markers, and absence of contaminants are required for any credibly characterized EV preparation, regardless of source.
Regulatory position
For cosmetic use, both plant-derived and mammalian EVs are regulated as cosmetic ingredients in most jurisdictions. The substantive regulatory difference shows up at the therapeutic end of the spectrum. Mammalian EV therapeutic products face complex cell-therapy-adjacent regulatory pathways under FDA, EMA, and Health Canada therapeutic frameworks. Plant-derived EVs, when used in cosmetic applications, operate within comparatively simpler botanical-ingredient regulatory frameworks that are a closer analogue to other plant-derived cosmetic actives.
Cosmetic products made with BioThera's material are cosmetics under Canada's Cosmetic Regulations, and their Health Canada cosmetic notification has been completed, so they can be legally distributed and sold in Canada. The material itself is characterized to standards well beyond what cosmetic regulation requires.
Practical positioning
Mammalian EVs carry the deeper clinical evidence base for therapeutic applications and are likely to remain the dominant modality for clinically administered EV interventions in regenerative medicine and oncology. Plant-derived EVs offer a more scalable manufacturing base, an established safety profile for cosmetic use, and sufficient preclinical evidence to support topical cosmetic positioning. They are not the same product class. They are not competing for the same use cases. The clean version of the comparison treats them as two adjacent modalities with overlapping biophysical properties and divergent commercial roles.
That framing is the foundation of how BioThera builds its platform. Plant-derived EVs are the entry point, not the ceiling: the platform is built to span both, and our research extends to mammalian sources, including human stem cell-derived vesicles, for applications where their biology is the better fit.